Biosimulation, which involves computer-aided simulation of biological processes and systems, finds extensive applications in drug discovery and development. The biosimulation market, valued at $2.8 billion in 2022, is expected to experience robust growth at a CAGR of 16.9% from 2022 to 2030.
The company we are profiling today is Simulations Plus Inc. (SLP), a provider of AI-powered technology solutions to enhance drug discovery, development, research, and regulatory approval processes, accelerating a drug's journey from conception to market. Its customers include companies involved in pharmaceuticals, biotechnology, agrotechnology, and cosmetics, as well as universities, hospitals, and government research organizations.
For comments and feedback: editorial@rttnews.com